These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39361016)

  • 1. Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations.
    Proudman D; Desai U; Gomes DA; Khomenko M; Martin S; Nellesen D; Neumann U; Grabowski H
    J Med Econ; 2024; 27(1):1253-1266. PubMed ID: 39361016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom.
    Sussex J; Feng Y; Mestre-Ferrandiz J; Pistollato M; Hafner M; Burridge P; Grant J
    BMC Med; 2016 Feb; 14():32. PubMed ID: 26908129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public funding and private investment for R&D: a survey in China's pharmaceutical industry.
    Qiu L; Chen ZY; Lu DY; Hu H; Wang YT
    Health Res Policy Syst; 2014 Jun; 12():27. PubMed ID: 24925505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anatomy of medical research: US and international comparisons.
    Moses H; Matheson DH; Cairns-Smith S; George BP; Palisch C; Dorsey ER
    JAMA; 2015 Jan; 313(2):174-89. PubMed ID: 25585329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019.
    Galkina Cleary E; Jackson MJ; Zhou EW; Ledley FD
    JAMA Health Forum; 2023 Apr; 4(4):e230511. PubMed ID: 37115539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An In-Depth Analysis of Public and Private Research Funding in Orthopaedic Surgery from 2015 to 2021.
    Shah AK; Burkhart RJ; Shah VN; Gould HP; Acuña AJ; Kamath AF
    J Bone Joint Surg Am; 2024 Sep; 106(17):1631-1637. PubMed ID: 38603562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relative Contributions of NIH and Private Sector Funding to the Approval of New Biopharmaceuticals.
    Schulthess D; Bowen HP; Popovian R; Gassull D; Zhang A; Hammang J
    Ther Innov Regul Sci; 2023 Jan; 57(1):160-169. PubMed ID: 36057746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National expenditure on health research in South Africa: How has the landscape changed in the past decade?
    Barnabé MA; Gordon R; Ramjee G; Loots G; Blackburn JM
    S Afr Med J; 2020 Mar; 110(4):274-283. PubMed ID: 32657738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hong Kong domestic health spending: financial years 1989/90 to 2008/09.
    Tin KY; Tsoi PK; Lee YH; Tsui EL; Lam DW; Chui AW; Lo SV
    Hong Kong Med J; 2012 Aug; 18(4 Suppl 4):1-23. PubMed ID: 22947491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.
    Garcia MM; Azevedo PS; Mirelman A; Safatle LP; Iunes R; Bennie MC; Godman B; Guerra Junior AA
    Front Pharmacol; 2020; 11():370. PubMed ID: 32351382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financial anatomy of biomedical research.
    Moses H; Dorsey ER; Matheson DH; Thier SO
    JAMA; 2005 Sep; 294(11):1333-42. PubMed ID: 16174691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Government and Pharmaceutical Innovation: Looking Back and Looking Ahead.
    Sampat BN
    J Law Med Ethics; 2021; 49(1):10-18. PubMed ID: 33966646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Australia's 'free-ride' in pharmaceuticals: can it last?
    Kemp R
    Aust Health Rev; 1996; 19(1):81-94. PubMed ID: 10157539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Funding of US biomedical research, 2003-2008.
    Dorsey ER; de Roulet J; Thompson JP; Reminick JI; Thai A; White-Stellato Z; Beck CA; George BP; Moses H
    JAMA; 2010 Jan; 303(2):137-43. PubMed ID: 20068207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public and private donor financing for health in developing countries.
    Howard LM
    Infect Dis Clin North Am; 1991 Jun; 5(2):221-34. PubMed ID: 1869807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of health sector non-governmental organizations: policy options.
    Gilson L; Sen PD; Mohammed S; Mujinja P
    Health Policy Plan; 1994 Mar; 9(1):14-24. PubMed ID: 10133097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Return on investment: a fuller assessment of the benefits and cost savings of the US publicly funded family planning program.
    Frost JJ; Sonfield A; Zolna MR; Finer LB
    Milbank Q; 2014 Dec; 92(4):696-749. PubMed ID: 25314928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovation in the pharmaceutical industry: New estimates of R&D costs.
    DiMasi JA; Grabowski HG; Hansen RW
    J Health Econ; 2016 May; 47():20-33. PubMed ID: 26928437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Does the public sector have an independent research role in the development of drugs?].
    Poulsen HE; Grønlykke TB
    Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hong Kong domestic health spending: financial years 1989/90 to 2005/06.
    Tin KY; Tsoi PK; Leung ES; Tsui EL; Lam DW; Tsang CS; Lo SV
    Hong Kong Med J; 2010 Feb; 16 Suppl 2():1-23. PubMed ID: 20393228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.